QIAGEN Strengthens QIAstat-Dx With New Barcelona Site to Drive Growth in Infectious Diseases and Precision Medicine Testing
QIAGEN announced plans to relocate its QIAstat-Dx operations to a new 8,000-square-meter site in Esplugues de Llobregat, Barcelona, set to open in early 2026. The facility will support the entire value chain for the QIAstat-Dx system, which performs syndromic testing for infectious diseases and precision medicine applications. The site will include R&D, manufacturing, sales, marketing, and regulatory operations, featuring digitalized production lines and LEED Platinum certification. The expansion aims to strengthen QIAGEN's diagnostic capabilities and support recent partnerships with Eli Lilly and AstraZeneca. The QIAstat-Dx system currently has FDA clearance for four panels and CE-marking for two panels under IVDR.
QIAGEN ha annunciato piani per trasferire le proprie operazioni QIAstat-Dx in una nuova sede di 8.000 metri quadrati a Esplugues de Llobregat, Barcellona, prevista per aprire all'inizio del 2026. La struttura supporterà l'intera catena del valore del sistema QIAstat-Dx, che esegue test sindromici per malattie infettive e applicazioni di medicina di precisione. Il sito includerà operazioni di R&D, produzione, vendite, marketing e normative, con linee di produzione digitalizzate e certificazione LEED Platinum. L'espansione mira a rafforzare le capacità diagnostiche di QIAGEN e a sostenere le recenti partnership con Eli Lilly e AstraZeneca. Il sistema QIAstat-Dx ha attualmente l'approvazione FDA per quattro pannelli e il marchio CE per due pannelli sotto IVDR.
QIAGEN anunció planes para trasladar sus operaciones de QIAstat-Dx a un nuevo sitio de 8,000 metros cuadrados en Esplugues de Llobregat, Barcelona, que abrirá a principios de 2026. La instalación apoyará toda la cadena de valor del sistema QIAstat-Dx, que realiza pruebas sindrómicas para enfermedades infecciosas y aplicaciones de medicina de precisión. El sitio incluirá operaciones de I+D, fabricación, ventas, marketing y regulatorias, con líneas de producción digitalizadas y certificación LEED Platinum. La expansión tiene como objetivo fortalecer las capacidades de diagnóstico de QIAGEN y apoyar las recientes asociaciones con Eli Lilly y AstraZeneca. El sistema QIAstat-Dx actualmente cuenta con la aprobación de la FDA para cuatro paneles y marcado CE para dos paneles bajo IVDR.
QIAGEN은 바르셀로나에 위치한 에스플루게스 데 로블레갓에 8,000 제곱미터 규모의 새 QIAstat-Dx 운영 센터를 2026년 초 개소할 계획을 발표했습니다. 이 시설은 감염병에 대한 증후군 테스트 및 정밀 의료 응용 프로그램을 수행하는 QIAstat-Dx 시스템의 전체 가치 사슬을 지원할 것입니다. 이 사이트는 R&D, 제조, 판매, 마케팅 및 규제 작업을 포함하며, 디지털화된 생산 라인과 LEED 플래티넘 인증을 갖추고 있습니다. 이번 확장은 QIAGEN의 진단 능력을 강화하고 Eli Lilly와 AstraZeneca와의 최근 파트너십을 지원하는 것을 목표로 하고 있습니다. 현재 QIAstat-Dx 시스템은 FDA에서 네 개 패널에 대한 승인을 받았고 IVDR에 따라 두 개의 패널에 대해 CE 마크를 획득했습니다.
QIAGEN a annoncé des plans pour transférer ses opérations QIAstat-Dx vers un nouveau site de 8 000 mètres carrés à Esplugues de Llobregat, Barcelone, qui devrait ouvrir début 2026. L'installation soutiendra toute la chaîne de valeur du système QIAstat-Dx, qui réalise des tests syndromiques pour les maladies infectieuses et des applications en médecine de précision. Le site comprendra des opérations de R&D, de fabrication, de vente, de marketing et réglementaires, avec des lignes de production numérisées et une certification LEED Platinum. L'expansion vise à renforcer les capacités de diagnostic de QIAGEN et à soutenir les récentes partenariats avec Eli Lilly et AstraZeneca. Le système QIAstat-Dx dispose actuellement d'une autorisation de la FDA pour quatre panneaux et d'un marquage CE pour deux panneaux sous l'IVDR.
QIAGEN kündigte Pläne an, seine QIAstat-Dx-Operationen in einen neuen 8.000 Quadratmeter großen Standort in Esplugues de Llobregat, Barcelona, zu verlagern, der Anfang 2026 eröffnet werden soll. Die Einrichtung wird die gesamte Wertschöpfungskette des QIAstat-Dx-Systems unterstützen, das syndromische Tests für infektionsbedingte Krankheiten und Anwendungen der Präzisionsmedizin durchführt. Der Standort wird Forschungs- und Entwicklungs-, Produktions-, Vertriebs-, Marketing- und Regulierungsoperationen umfassen, mit digitalisierten Produktionslinien und einer LEED-Platin-Zertifizierung. Die Erweiterung zielt darauf ab, die diagnostischen Fähigkeiten von QIAGEN zu stärken und die jüngsten Partnerschaften mit Eli Lilly und AstraZeneca zu unterstützen. Das QIAstat-Dx-System hat derzeit die FDA-Zulassung für vier Panels und die CE-Kennzeichnung für zwei Panels im Rahmen der IVDR.
- Multi-year investment in new state-of-the-art facility to expand diagnostic capabilities
- Strategic partnerships with major pharma companies (Eli Lilly, AstraZeneca) for precision medicine applications
- Four FDA-cleared panels and two CE-marked panels under IVDR
- Expansion into new testing applications beyond infectious diseases
- None.
Insights
The expansion of QIAstat-Dx operations represents a significant strategic move in the diagnostics sector. The new
The partnership expansion with pharmaceutical giants Eli Lilly and AstraZeneca signals strong commercial potential beyond infectious diseases. The system's ability to provide rapid syndromic testing with detailed Ct values and amplification curves offers a competitive advantage in the growing point-of-care diagnostics market. The FDA clearance for four panels and CE-IVDR marking for two panels provide solid regulatory foundation for market expansion.
This strategic investment positions QIAGEN to capture larger market share in the rapidly growing syndromic testing market. The expansion into precision medicine applications, particularly through partnerships with major pharmaceutical companies, opens new revenue streams beyond traditional diagnostic testing. The vertical integration of R&D, manufacturing and commercial operations in one location should improve operational efficiency and accelerate product development cycles.
The focus on digitalized production lines and sustainable facilities demonstrates forward-thinking operational strategy that could reduce long-term costs. The selection of Barcelona leverages existing expertise and infrastructure while providing access to a rich talent pool and research ecosystem.
-
New
Barcelona site to help drive global expansion of QIAstat-Dx as QIAGEN expands local presence with multi-year investment
- Site in Esplugues de Llobregat to serve as an innovation hub for QIAstat-Dx, supporting the development of infectious disease tests and precision medicine applications
Set to open in early 2026, the new site will cover the entire value chain for the QIAstat-Dx system, which is used for syndromic testing to identify the cause of an illness – especially in the areas of respiratory, gastrointestinal and meningitis / encephalitis conditions.
QIAstat-Dx is also being developed for use in precision medicine, in particular to support the expansion of recent partnerships announced with Eli Lilly and AstraZeneca. In precision medicine applications, QIAstat‑Dx for instance enables specialty care providers to perform genotyping whilst patients undergo routine clinical examination, thus enabling fast decision-making for potential suitability for certain genomically targeted medicines.
The new site builds on the long-standing presence of QIAGEN in the
“QIAstat-Dx demonstrated its value during the COVID-19 pandemic, supporting healthcare providers with rapid syndromic testing and crucial information when time mattered most,” said Thierry Bernard, CEO of QIAGEN. “Now we are building on this success by expanding the QIAstat-Dx pipeline to address a broader spectrum of healthcare needs. This means both expanding the range of pathogens for infectious disease testing as well as developing solutions for other disease areas and precision medicine applications.”
QIAGEN can also build on the local expertise in the QIAstat-Dx technology, which was originally developed by a start-up from
The Esplugues de Llobregrat site will enable QIAGEN to advance diagnostic capabilities in infectious diseases and beyond, helping to meet the growing demand for rapid diagnostics in diverse healthcare settings, from hospitals and clinics to decentralized testing points. The site will span 8,000 square meters and include offices, manufacturing lines, clean rooms, laboratories and logistics areas. The base building of the new facility has received LEED Platinum Certification, the highest standard in energy-efficient and environmentally responsible building design. The fit-out of the new facility will also meet this high standard and will be equipped with digitalized production lines.
The QIAstat-Dx system, designed for laboratory use, employs cost-efficient, single-use cartridges with built-in sample processing and on-board reagents. Utilizing multiplex real-time PCR, it detects and differentiates between multiple genetic targets, with results in about an hour. QIAstat-Dx also provides easy‑to‑view cycle threshold (Ct) values and amplification curves, offering additional insights not available with end-point PCR or other techniques.
Four QIAstat-Dx panels have been cleared by the
The system already has a strong footprint in infectious disease testing and will be further strengthened by accelerating innovations and expanding the testing menu to a broader range of pathogens, such as blood culture identification and complicated urinary tract infections
QIAGEN has already signed three partnerships with pharma companies including Eli Lilly and AstraZeneca to expand QIAstat‑Dx beyond infectious diseases. The new facilities will support this expansion into other disease areas such as neurodegenerative, metabolic, inflammatory and other genetically driven chronic diseases.
For more information on QIAstat-Dx visit https://www.qiagen.com/de-us/applications/syndromic-testing.
About QIAGEN
QIAGEN N.V., a
Forward-Looking Statement
Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the
Source: QIAGEN N.V.
Category: Corporate
View source version on businesswire.com: https://www.businesswire.com/news/home/20241128928344/en/
QIAGEN:
Investor Relations
John Gilardi, +49 2103 29 11711
Domenica Martorana, +49 2103 29 11244
e-mail: ir@QIAGEN.com
Public Relations
Thomas Theuringer, +49 2103 29 11826
Lisa Specht, +49 2103 29 14181
e-mail: pr@QIAGEN.com
Source: QIAGEN N.V.
FAQ
When will QIAGEN's new QIAstat-Dx facility in Barcelona open?
How many panels has QGEN's QIAstat-Dx system received FDA clearance for?
Which pharmaceutical companies has QGEN partnered with for QIAstat-Dx precision medicine applications?
How large is QGEN's new Barcelona facility for QIAstat-Dx?
